Neuroactive Steroid Modulation for Alzheimer’s Cognitive Decline
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Alzheimer's disease, particularly those targeting beta-amyloid deposition and tau hyperphosphorylation, have not shown clinical benefit in improving cognitive function and dementia symptoms.
Innovation Solution
Administration of NMDA receptor positive allosteric modulators, anti-amyloid beta antibodies, or CYP46A1 inhibitors, either alone or in combination, to treat or prevent Alzheimer's disease and associated cognitive impairments, with specific compounds and dosages specified for improving executive function, working memory, and learning.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If current medications for Alzheimer's disease are used to manage behavioral and psychological symptoms, then symptomatic relief is achieved, but cognitive function and dementia progression are not improved
Solution Approach 1:
The patent extracts and targets the specific pathological mechanisms of Alzheimer's disease (beta-amyloid deposition, tau hyperphosphorylation, neuroinflammation, vascular changes) rather than treating only symptoms. This extraction of the core pathological problem enables development of disease-modifying therapies that address the root causes rather than just managing behavioral symptoms.
Solution Approach 2:
Instead of continuing with symptomatic management approaches that have failed to improve cognitive function, the patent inverts the strategy by focusing on disease-modifying treatments that target underlying pathology. This inversion shifts from managing symptoms to addressing the fundamental disease processes driving cognitive decline.
2Reliability
If agents targeting beta-amyloid deposition and tau hyperphosphorylation are administered, then underlying pathology is addressed, but clinical benefit in cognitive function is not achieved
Solution Approach 1:
The patent employs a composite therapeutic approach combining multiple mechanisms of action: NMDA receptor positive allosteric modulators (enhancing glutamatergic transmission), anti-amyloid beta antibodies (clearing beta-amyloid plaques), and CYP46A1 inhibitors (modulating cholesterol metabolism and reducing neuroinflammation). This composite strategy addresses multiple pathological pathways simultaneously, overcoming the limitations of single-target therapies.
Solution Approach 2:
The patent utilizes parameter changes by modifying neurotransmitter system dynamics through NMDA receptor modulation. By enhancing glutamatergic transmission at the receptor level, the therapy changes the functional parameter of synaptic plasticity and cognitive processing, providing cognitive benefits beyond what structural pathology targeting alone can achieve.
3Productivity
If NMDA receptor positive allosteric modulators are administered, then cognitive functions are enhanced, but the mechanism of action differs from conventional symptomatic treatments
Solution Approach 1:
The NMDA receptor positive allosteric modulator acts as an intermediary substance that enhances endogenous glutamatergic transmission without directly activating NMDA receptors. This intermediary mechanism provides cognitive enhancement by optimizing the function of the existing neurotransmitter system, offering a novel pathway distinct from conventional symptomatic treatments while maintaining physiological compatibility.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These treatments demonstrate potential in enhancing cognitive functions such as executive function, working memory, and learning, and may slow cognitive decline in Alzheimer's disease.
Implementation Method 1
NMDA receptors are ligand-gated ion channels that admit Ca2+ after binding of the neurotransmitters, glutamate and glycine, and are fundamental to excitatory neurotransmission and normal CNS function
Data Source
AI summary
The present disclosure relates to compositions, kits and methods of treating Alzheimer's disease comprising administering an NMD A receptor positive allosteric modulator or a CYP46A1 inhibitor.